About: Hypothesis for the management and treatment of the COVID-19-induced acute respiratory distress syndrome and lung injury using mesenchymal stem cell-derived exosomes

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Hypothesis for the management and treatment of the COVID-19-induced acute respiratory distress syndrome and lung injury using mesenchymal stem cell-derived exosomes Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Hypothesis for the management and treatment of the COVID-19-induced acute respiratory distress syndrome and lung injury using mesenchymal stem cell-derived exosomes
Creator	Mahmoudi, Mohammad Soudi, Sara Hashemi, Seyed Hashemi, Hashemi, S Seyed, Mahmoud Taghavi-Farahabadi, Mahsa
Source	Elsevier; Medline; PMC
abstract	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a member of the coronaviridae that causes respiratory disorders. After infection, large amounts of inflammatory cytokines are secreted, known as the cytokine storm. These cytokines can cause pulmonary damage induced by inflammation resulting in acute respiratory distress syndrome (ARDS), and even death. One of the therapeutic approaches for treatment of ARDS is a mesenchymal stem cell (MSC). MSCs suppress inflammation and reduce lung injury through their immunomodulatory properties. MSCs also have the potential to prevent apoptosis of the lung cells and regenerate them. But our suggestion is using MSCs-derived exosomes. Because these exosomes apply the same immunomodulatory and tissue repair effects of MSCs and they don’t have problems associated to cell maintenance and injections. For investigation the hypothesis, MSCs should be isolated from tissues and characterized. Then, the exosomes should be isolated from the supernatants and characterized. These exosomes should be injected into a transgenic animal for COVID-19. In the final section, lung function assessment, histological examination, micro-CT, differential leukocyte, viral load analysis, cytokine assay, and CRP level analysis can be investigated. COVID-19 treatment is currently focused on supportive therapies and no vaccine has not been developed for it, so, numerous research studies are needed to find potential. Since the pathogenesis of this disease was identified in previous studies and can cause lung injury with ARDS, so, investigation of the therapeutic approaches that can suppress inflammation, cytokine storm and ARDS can be helpful in finding a novel therapeutic approach for this disease.
has issue date	2020-05-22(xsd:dateTime)
bibo:doi	10.1016/j.mehy.2020.109865
bibo:pmid	32562911
has license	no-cc
sha1sum (hex)	203465d83ebc574c7b4e683273a971756743548b
schema:url	https://doi.org/10.1016/j.mehy.2020.109865
resource representing a document's title	Hypothesis for the management and treatment of the COVID-19-induced acute respiratory distress syndrome and lung injury using mesenchymal stem cell-derived exosomes
has PubMed Central identifier	PMC7242964
has PubMed identifier	32562911
schema:publication	Med Hypotheses
resource representing a document's body	covid:203465d83ebc574c7b4e683273a971756743548b#body_text
is schema:about of	named entity 'https' named entity 'Journal' named entity 'management' named entity 'Hypothesis' named entity 'TREATMENT' named entity 'stem' named entity 'cite' named entity 'Medical Hypotheses' named entity 'doi' named entity 'lung injury' named entity 'mesenchymal stem cell' named entity 'COVID-19' named entity 'acute respiratory distress syndrome' named entity 'lung injury' named entity 'lung injury' named entity 'COVID' named entity 'prostaglandin E2' named entity 'histological examination' named entity 'ARDS' named entity 'cGAS' named entity '11 March 2020' named entity 'immune responses' named entity 'immunopathogenesis' named entity 'cytokines' named entity 'lung' named entity 'exosomes' named entity 'bone marrow' named entity 'cell mediated immunity' named entity 'China' named entity 'MSCs' named entity 'exosomes' named entity 'signaling pathways' named entity 'SARS' named entity 'MSCs' named entity 'immunomodulatory' named entity 'MSCs' named entity 'exosomes' named entity 'ARDS' named entity 'cytoplasm' named entity 'MERS-CoV' named entity 'pattern recognition receptors' named entity 'miR-146a' named entity 'effector' named entity 'growth factors' named entity 'angiotensin-converting' named entity 'viruses' named entity 'animal models' named entity 'inflammatory cytokines' named entity 'exosomes' named entity 'inflammation' named entity 'HSV-1' named entity 'CMV' named entity 'Middle East respiratory syndrome coronavirus' named entity 'ARDS' named entity 'LPS' named entity 'neutrophils' named entity 'NF-κB' named entity 'inflammation' named entity 'CRP' named entity 'osteogenic induction' named entity 'SARS-CoV-2' named entity 'CD9' named entity 'ARDS' named entity 'COVID' named entity 'exosomes' named entity 'animal model' named entity 'cytokine storm' named entity 'pathogens' named entity 'COVID' named entity 'MSCs' named entity 'World Health Organization' named entity 'apoptosis' named entity 'vascular endothelial growth factor' named entity 'exosomes' named entity 'lung'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software